The global cirrhosis management market is projected to grow steadily, with its valuation rising from USD 725 million in 2023 to USD 1,052.3 million by 2033, reflecting a compound annual growth rate (CAGR) of 3.8% during the forecast period. This growth is significantly higher than the market’s historical CAGR of 2.7% observed from 2018 to 2022, underscoring the rising demand for effective cirrhosis treatment and management solutions.
The expansion of the market is primarily driven by the increasing incidence of liver cirrhosis, which is being fueled by a global rise in hepatitis infections, particularly hepatitis B and C. Hepatitis-related liver damage remains one of the leading causes of cirrhosis, creating a growing need for effective diagnostic, monitoring, and treatment solutions. With the rising burden of chronic liver diseases, healthcare systems worldwide are placing greater emphasis on early detection and long-term disease management.
Innovations in diagnostic technologies and therapeutic options for cirrhosis are further propelling the market. Advanced non-invasive diagnostic methods such as elastography and serum biomarkers are being widely adopted to detect liver fibrosis and assess the severity of cirrhosis. Furthermore, the development of targeted therapies and antiviral drugs aimed at managing hepatitis infections is expected to bolster the market for cirrhosis management.
As healthcare providers prioritize chronic disease management and liver health, investment in R&D for novel cirrhosis treatments is on the rise. Market players are focused on the development of advanced therapies that offer better patient outcomes, reduce hospitalization rates, and lower healthcare costs. Public health initiatives aimed at raising awareness of liver health and hepatitis prevention are also expected to support long-term market growth.
Get the Comprehensive Full Report Now – https://www.futuremarketinsights.com/reports/cirrhosis-management-market
Key Takeaways:
- The global cirrhosis management market is projected to grow from US$ 725 million in 2023 to US$ 1,052.3 million by 2033, with a CAGR of 3.8%.
- The market’s expansion is attributed to the rising incidence of liver cirrhosis, driven by the global increase in hepatitis B and C infections.
- Innovations in diagnostic technologies, such as elastography and biomarker-based detection, are improving early diagnosis and disease monitoring.
- The market is witnessing growth in targeted therapies and antiviral drugs, enhancing treatment options for cirrhosis patients.
- Public health initiatives and investments in R&D are driving advancements in liver disease management, supporting sustained market growth through 2033.
Market Drivers
- Increasing Incidence of Liver Cirrhosis: The rising number of liver cirrhosis cases, primarily due to hepatitis infections, is a significant factor driving market growth.
- Growing Awareness and Diagnosis: Enhanced awareness about liver diseases and improved diagnostic capabilities are leading to earlier detection and management of cirrhosis.
- Advancements in Treatment Options: Ongoing research and development in treatment methodologies are improving patient outcomes and expanding the therapeutic options available for managing cirrhosis.
- Aging Population: An increasing elderly population, who are more susceptible to liver diseases, is contributing to the demand for effective cirrhosis management solutions.
- Healthcare Investments: Increased investments in healthcare infrastructure and liver disease management programs are supporting market expansion.
Regional Insights
- North America: Expected to hold the largest market share due to advanced healthcare systems and high rates of liver disease diagnosis and treatment.
- Asia-Pacific: Anticipated to experience significant growth driven by rising healthcare expenditures, increasing prevalence of liver diseases, and improvements in healthcare infrastructure.
Challenges
- High Treatment Costs: The costs associated with advanced treatments for cirrhosis may limit access for some patients, particularly in low-income regions.
- Regulatory Hurdles: Navigating complex regulatory environments can pose challenges for manufacturers introducing new therapies into the market.
Market Competition
Some of the key participants present in the global Cirrhosis Management market include Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, B. Braun Medical Inc., Conatus Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Stempeutics Research Pvt Ltd, Epic Research & Diagnostics, Inc., Inc., and NovaShunt AG among others.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, and B. Braun Medical Inc., account for a considerable market size, several regional-level players are also operating across key growth regions, particularly in North America.
Recent Key Developments in the Market Include
- In February 2021, B.Braun Medical Inc., an eminent in infusion therapy and pain management, announced that it received approval from the United States FDA for the first and only Acetaminophen Injection available in various doses. Acetaminophen Injection contains acetaminophen, which has been associated with cases of acute liver failure, resulting in liver transplant, and death.
- In September 2021, Merck (MSD) announced that its antibody Keytruda met the primary endpoint of overall survival (OS) in Phase III KEYNOTE-394 clinical trial in Asian patients with advanced hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
Key Companies Profiled
- B. Braun Medical Inc.
- Alliancells Bioscience Corporation Ltd.
- Histogen Inc.
- Stempeutics Research Pvt. Ltd.
- Epic Research & Diagnostics Inc.
- Theravance Biopharma R&D Inc.
- Sequana Medical AG
Key Segments Profiled in the Cirrhosis Management Industry Survey
By Treatment:
- Treating Cirrhosis Causes
- Antiviral Medications for Hepatitis B & C
- Corticosteroids
- Symptomatic Treatment
- Analgesics
- Treatment of Portal Hypertension (Beta-Blockers, Nitrates)
- Treatment of Edema and Ascites (Diuretics, Antibiotics)
- Avoid Complications
- Banding Procedures/Band Ligation of Varics
- Dialysis
- Treatment of Osteoporosis
- Vaccination for Flu and Other Complications
- Liver Transplantation
By Disease Indication:
- Alcoholic Liver
- Non-Alcoholic Liver
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Research Institutes
- Dialysis Centers
- Clinics
- Other Settings
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
